Oculis Holding AG

OCS Healthcare Biotechnology

Oculis Holding AG’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 85.7% from fiscal 2024.

Revenue
−97.2%
EPS
+9.20%
Free cash flow
−20.9%
Total debt
−4.44%

Quarter to September 2026, against a year earlier

7.49 0.66 +9.66%
Market cap
$421.6M
P/E
0.0×
Fwd P/E
−4.4×
Dividend yield
—
F-score
4/9
Altman Z
10.51
Beneish M
n/a
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
490.29 577.09 1,121.34 720.95
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(26.08) (33.41) (80.03) (57.88)
P/B ratio
2.25 3.06 6.24 4.41
EV/Sales
272.79 382.70 920.42 545.04
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(3.71) (6.82) (16.04) (9.65)
Current Ratio
10.41 8.35 5.18 5.96
Net Debt/EBITDA
8.91 9.68 10.21 9.94
Debt/Equity
0.01 0.01 0.01 0.01
Earnings Yield
(18.63%) (12.81%) (8.15%) (11.55%)
Free Cash Flow Yield
(14.99%) (9.73%) (5.12%) (7.83%)
Free Cash Flow per Share
(0.36) (0.42) (0.33) (0.34)
Book value per Share
4.16 4.53 4.26 4.53
Free Cash Flow
(22.14) (25.45) (19.58) (18.01)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026